Logo

PRPH

ProPhase Labs, Inc.

PRPH

ProPhase Labs, Inc. • NASDAQ
$0.21 ▲ 15.08% (+0.03)
Market Cap $9.37 M
52w High $0.93
52w Low $0.16
Dividend Yield 0%
P/E -0.11
Volume 1.78M
Outstanding Shares 45.00M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $883K ▼ $4.641M ▲ $-6.839M ▼ -774.519% ▼ $-0.16 ▼ $-4.392M ▼
Q2-2025 $1.247M ▼ $4.628M ▲ $-4.472M ▼ -358.621% ▼ $-0.11 ▼ $-3.566M ▼
Q1-2025 $1.431M ▲ $4.189M ▼ $3.966M ▲ 277.149% ▼ $0.21 ▲ $-2.536M ▲
Q4-2024 $-2.484M ▼ $15.491M ▲ $-34.359M ▼ 1.383K% ▲ $-1.58 ▼ $-14.317M ▼
Q3-2024 $3.146M $7.772M $-6.587M -209.377% $-0.35 $-5.431M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $405K ▲ $65.702M ▲ $58.841M ▲ $6.861M ▼
Q2-2025 $171K ▲ $42.041M ▼ $30.605M ▼ $11.436M ▼
Q1-2025 $88K ▼ $50.591M ▼ $34.993M ▼ $15.598M ▲
Q4-2024 $678K ▼ $63.2M ▼ $55.847M ▲ $7.353M ▼
Q3-2024 $1.096M $91.808M $53.682M $38.126M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-6.839M ▼ $-21.523M ▼ $-920K ▼ $3.722M ▲ $236K ▲ $-21.523M ▼
Q2-2025 $-4.472M ▲ $-247K ▲ $67K ▼ $261K ▼ $81K ▲ $-247K ▲
Q1-2025 $-4.678M ▲ $-3.381M ▼ $853K ▲ $1.938M ▼ $-590K ▼ $-3.381M ▼
Q4-2024 $-30.52M ▼ $2.164M ▲ $-40K ▲ $3.735M ▲ $-416K ▲ $2.399M ▲
Q3-2024 $-6.587M $-4.03M $-97K $2.856M $-1.271M $-4.206M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Consumer Products Segment
Consumer Products Segment
 $0 ▲$0 ▲$0 ▲$0 ▲
Consumer Products
Consumer Products
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been volatile, with a pandemic-era surge followed by a clear pullback more recently. The business moved from modest profitability during the testing boom to noticeable losses in the last two years as that temporary demand faded and the company invests in new areas. Margins that once looked healthy during the peak revenue period have compressed again, so the income statement now reflects a developing company in investment mode rather than a mature, consistently profitable operator. The main risk is that spending on growth (diagnostics, genomics, new consumer products) is running ahead of current revenue, and it’s not yet clear how quickly the new businesses can scale to restore sustained profitability.

Balance Sheet

Balance Sheet The balance sheet is relatively small and has weakened recently. Total assets have stepped down from prior levels, and the equity cushion has shrunk, suggesting recent losses and possibly some write-downs. Debt has crept up while cash remains modest, so financial flexibility is more limited than a few years ago. The company does not appear overbuilt, but it also does not have a large buffer to absorb prolonged losses, making disciplined cost control and timely execution of its growth plans especially important.

Cash Flow

Cash Flow Cash generation is inconsistent and closely tied to revenue spikes. During the strong testing year, the business produced solid cash from operations, but most years around that have seen cash outflows from day‑to‑day operations. Free cash flow has generally been negative except in that standout year, though capital spending itself is light. This pattern underlines that the company is still dependent on external funding or one‑off events to support its growth initiatives and cannot yet rely on its core operations to fully fund expansion on a steady basis.

Competitive Edge

Competitive Edge ProPhase is trying to carve out a niche at the crossroads of diagnostics, genomics, and consumer health, rather than competing as a traditional, single‑line drug maker. Its key advantages are: a patented esophageal cancer test with promising early data, ownership of a low‑cost whole genome sequencing platform, and a long‑standing retail distribution network for consumer products. These strengths give it differentiated tools and channels, but it competes in crowded, fast‑moving markets against much larger and better‑funded players in genomics, diagnostics, and over‑the‑counter health. The real test of its competitive position will be whether it can convert these assets into broad clinical adoption and strong consumer brand recognition before rivals close the gap.

Innovation and R&D

Innovation and R&D The company is clearly innovation‑led. Its pipeline ranges from the BE‑Smart esophageal cancer test, to whole genome sequencing services and subscription‑style DNA insights, to new immune‑support supplements and longer‑term AI‑driven drug discovery. This breadth shows ambition and creative use of its genomics data and manufacturing base. However, much of this value is still in the future: BE‑Smart is approaching commercialization, the new genomics offerings need market traction, and the AI drug discovery work is early stage. Execution risk is high—regulatory hurdles, clinical validation, physician adoption, consumer education, and marketing all need to line up for these R&D efforts to translate into meaningful, recurring revenue.

Summary

ProPhase is in a transition from a small consumer‑health business that briefly benefited from pandemic testing demand to a diversified, innovation‑focused healthcare platform. Financially, the company has swung from profit to loss, its balance sheet cushion has thinned, and cash flow is not yet reliably positive—signs of a business still in a build‑out phase. Strategically, it holds several interesting assets: a patented high‑potential cancer test, a direct‑to‑consumer genomics platform, in‑house manufacturing, and broad retail distribution. The opportunity lies in successfully commercializing these innovations and building durable revenue streams around them. The key risks are execution, timing, competitive pressure, and limited financial headroom if the ramp‑up takes longer than planned. Overall, this looks like an early‑stage, high‑uncertainty story where future outcomes depend heavily on how well management delivers on its pipeline and cost‑saving plans over the next few years.

NEWS

November 26, 2025 · 8:00 AM UTC

Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on December 1

Read more

November 19, 2025 · 8:13 AM UTC

ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.

Read more

November 18, 2025 · 8:00 AM UTC

ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19

Read more

November 17, 2025 · 8:00 AM UTC

ProPhase Labs Urges Shareholders to Vote by November 23 on Proxy Proposals

Read more

October 29, 2025 · 8:30 AM UTC

ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology

Read more